<DOC>
	<DOCNO>NCT02670746</DOCNO>
	<brief_summary>The objective study prospectively assess use treatment outcomes nab-paclitaxel plus gemcitabine pancreatic ductal adenocarcinoma Netherlands . Additional objective monitor incidence reversibility neuropathy treatment , assess patient 's Quality life treat nab-paclitaxel/gemcitabine evaluate use resource come treat metastatic pancreatic cancer .</brief_summary>
	<brief_title>A Study Assess Clinical Patient Reported Outcomes With Nab-paclitaxel Combination With Gemcitabine Route Clinical Practice Treating Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Patients 18 year age understand voluntarily sign informed consent form . Patients treat pancreatic adenocarcinoma . Patients currently treat metastatic pancreatic cancer therapy nabpaclitaxel plus gemcitabine Refusal participate study . Women pregnant breastfeeding . Hypersensitivity active substance excipients . Participation interventional trial period treatment nabpaclitaxel</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Pancreatic Cancer</keyword>
	<keyword>Observational</keyword>
	<keyword>Nab-Paclitaxel</keyword>
	<keyword>Abraxane</keyword>
	<keyword>ABI-007</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Non-interventional</keyword>
	<keyword>Netherlands</keyword>
	<keyword>Quality Life</keyword>
</DOC>